ClinicalTrials.gg

Program

brincidofovir

Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.

Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.

Furthest: phase 3, since Jun 11, 201019 company-led studies, 1 open or runningNext primary completion: Jan 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals140 open or runningphase 3since Jun 11, 2010Oct 23, 2008none ahead
SymBio Pharmaceuticals41 open or runningphase 3since Jan 20, 2026Aug 29, 2020Jan 31, 2028phase 3 · NCT07387367
Emergent BioSolutions10 open or runningphase 1since Jun 5, 2023Jun 5, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Oct 23, 2008.

  1. Nov 12, 2010Phase 2 study in Adenovirus DiseaseJazz Pharmaceuticals · NCT01241344 · 52 enrolled · United States
  2. Jun 30, 2011Phase 1 study in Hepatic ImpairmentJazz Pharmaceuticals · NCT05391724 · 25 enrolled · United States
  3. Jan 14, 2013Phase 3 study in CMVJazz Pharmaceuticals · NCT01769170 · 452 enrolled · United States, Belgium, Canada
  4. Mar 12, 2014Phase 3 study in Adenoviridae InfectionsJazz Pharmaceuticals · NCT02087306 · 201 enrolled · United States
  5. Oct 7, 2014Phase 2 study in Ebola VirusJazz Pharmaceuticals · NCT02271347
  6. May 7, 20152 phase 3 studies in Cytomegalovirus InfectionsJazz Pharmaceuticals · NCT02439970, NCT02439957
  7. Nov 8, 2017Phase 2 study in Adenoviridae InfectionsJazz Pharmaceuticals · NCT03339401 · 29 enrolled · United States, France, Germany and more
  8. Apr 26, 2018Phase 2 study in Adenoviridae InfectionsJazz Pharmaceuticals · NCT03532035 · United States, Italy, Spain
  9. Feb 12, 2020Phase 2 study in Hemorrhagic Fever, EbolaJazz Pharmaceuticals · NCT04268966
  10. Aug 29, 2020SymBio Pharmaceuticals's first study: phase 1 study in Drug Drug InteractionNew to SymBio PharmaceuticalsSymBio Pharmaceuticals · NCT04542252 · 13 enrolled · Japan
  11. Aug 16, 2022Phase 2 study in Kidney DiseasesSymBio Pharmaceuticals · NCT05511779 · 1 enrolled · Japan
  12. Jun 5, 2023Emergent BioSolutions's first study: phase 1 study in SmallpoxNew to Emergent BioSolutionsEmergent BioSolutions · NCT05935917 · 44 enrolled · United States
  13. Dec 24, 2024Phase 2 study in RecurrenceSymBio Pharmaceuticals · NCT06761677 · 43 enrolled · China, Japan, Singapore
  14. Jan 20, 2026Phase 3 study in Adenoviridae InfectionsPhase 3 reachedSymBio Pharmaceuticals · NCT07387367 · 180 planned · United States, Austria, Belgium and more

Ahead

  1. Jan 31, 2028Primary completion: phase 3 study in Adenoviridae InfectionsSymBio Pharmaceuticals · NCT07387367

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07387367Adenoviridae Infections · United States, Austria, Belgium and more3RecruitingSymBio PharmaceuticalsJan 31, 2028180
NCT06761677Recurrence · China, Japan, Singapore2SuspendedSymBio PharmaceuticalsOct 23, 202743
NCT05935917Smallpox · United States1CompletedEmergent BioSolutionsAug 14, 202344
NCT05511779Kidney Diseases · Japan2TerminatedSymBio PharmaceuticalsApr 13, 20231
NCT04542252Drug Drug Interaction · Japan1CompletedSymBio PharmaceuticalsDec 22, 202013
NCT04268966Hemorrhagic Fever, Ebola2WithdrawnJazz PharmaceuticalsNov 20150
NCT03532035Adenoviridae Infections · United States, Italy, Spain2WithdrawnJazz PharmaceuticalsMay 10, 20190
NCT03339401Adenoviridae Infections · United States, France, Germany and more2TerminatedJazz PharmaceuticalsMay 10, 201929
NCT02439970Cytomegalovirus Infections · United States3TerminatedJazz PharmaceuticalsJan 30, 20165
NCT02439957Cytomegalovirus Infections · United States3TerminatedJazz PharmaceuticalsMay 15, 20166
NCT02271347Ebola Virus2WithdrawnJazz PharmaceuticalsJan 20150
NCT02087306Adenoviridae Infections · United States3CompletedJazz PharmaceuticalsJun 2016201
NCT01769170CMV · United States, Belgium, Canada3CompletedJazz PharmaceuticalsDec 2015452
NCT05391724Hepatic Impairment · United States1CompletedJazz PharmaceuticalsSep 201125
NCT01241344Adenovirus Disease · United States2CompletedJazz PharmaceuticalsJun 201352
NCT01143181Adenoviridae Infections · United States3CompletedJazz PharmaceuticalsDec 2012210
NCT00942305Cytomegalovirus Infections · United States2CompletedJazz PharmaceuticalsJan 2012239
NCT00793598Viruria · United States2CompletedJazz PharmaceuticalsOct 201029
NCT00780182Healthy · United States1CompletedJazz PharmaceuticalsDec 200824

How it is read

Names in the registry

  • “Brincidofovir”, 15 entries
  • “CMX001”, 3 entries
  • “SyB V-1901”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
brincidofovir (Jazz Pharmaceuticals): development program | ClinicalTrials.gg